Physician profile
James Park
NPI 1073713772
$81,485.81
in general payments reported to CMS, 2019-2025
23 companies · $24K in 2025
The $24K reported for 2025 was more than what 85% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $11K · 2021: $6,070 · 2022: $2,939 · 2023: $42.19 · 2024: $145 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $10K · Travel and Lodging: $1,487 · Food and Beverage: $1,478 · Education: $17.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,184.00 |
| Consulting Fee | $10,060.00 |
| Travel and Lodging | $1,487.37 |
| Food and Beverage | $1,478.22 |
| Education | $17.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22,575.64 | 2019-2025 | Livdelzi |
| Celltrion, INC. | $20,838.34 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $11,546.84 | 2025 | Iqirvo |
| Abbvie INC. | $10,799.56 | 2019-2020 | |
| Mirum Pharmaceuticals, INC. | $6,669.46 | 2024-2025 | Livmarli |
| Madrigal Pharmaceuticals | $3,205.09 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $2,990.86 | 2019 | |
| Merck Sharp & Dohme LLC | $1,000.00 | 2019 | |
| Celltrion Healthcare Co., Ltd | $650.00 | 2021 | |
| Exelixis INC. | $535.08 | 2020 | |
| Histosonics, INC. | $172.86 | 2025 | |
| Amgen INC. | $130.83 | 2025 | Krystexxa |
| Integra Lifesciences Corporation | $125.46 | 2025 | Cusa Clarity, Duraseal Exact Spinal Sealant System, Codman Certas |
| Glaxosmithkline, LLC. | $50.15 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.19 | 2023 | Entyvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $37.70 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $28.60 | 2024 | |
| Shionogi INC | $27.04 | 2019 | |
| Orphalan INC | $25.82 | 2024 | Cuvrior |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.33 | 2019 | |
| Allergan, INC. | $15.96 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.